Influence of diabetes and hypercholesterolemia on laboratory methods for hereditary spherocytosis diagnosis

Elena Lazarova1, Béatrice Gulbis1

  • 1Laboratory of Hereditary RBC pathologies, Department of Clinical Chemistry, Laboratoire Hospitalier Universitaire de Bruxelles- Universitair laboratorium Brussel, Université Libre de Bruxelles, Bruxelles, Belgium.

Insights

Metabolic disorders like diabetes do not interfere with hereditary spherocytosis (HS) screening. Standard laboratory methods for diagnosing HS remain reliable even with co-existing conditions.

Area of Science:

  • Hematology
  • Clinical Diagnostics
  • Red Blood Cell Disorders

Background:

  • Hereditary spherocytosis (HS) causes hemolytic anemia due to reduced erythrocyte deformability.
  • HS diagnosis can be delayed in adults presenting with gallstones or splenomegaly.
  • Metabolic disorders, including diabetes and dyslipidemia, also impair red blood cell (RBC) deformability.

Purpose of the Study:

  • To evaluate the impact of common adulthood metabolic disorders on HS diagnostic tools.
  • To determine if diabetes, dyslipidemia, or metabolic syndrome affect HS screening and confirmatory tests.

Main Methods:

  • A workflow for HS diagnosis was applied to 95 pathological samples.
  • Samples included patients with diabetes, hypercholesterolemia, dyslipidemia, hypertriglyceridemia, and metabolic syndrome (MS).
  • Diagnostic methods included automated reticulocyte analysis, cryohemolysis test, and ektacytometry osmoscan analysis.

Main Results:

  • Automated reticulocyte indices flagged 4.2% of samples as potentially HS.
  • One diabetes sample (5%) and three MS samples (16.7%) fell within the HS zone.
  • Cryohemolysis test and osmoscan analysis showed no significant differences between pathological groups and controls.

Conclusions:

  • Concomitant metabolic disorders, including diabetes and hypercholesterolemia, do not interfere with standard HS screening and confirmatory laboratory methods.
  • The study confirms the reliability of current diagnostic tools for HS in patients with co-existing metabolic conditions.
Abstract